Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors
May 11 2022 - 4:00PM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, today announced
the appointment of David L. Johnson to its board of directors. Mr.
Johnson is a seasoned executive with 30 years of commercial and
operational experience in the biopharmaceutical industry.
“David has an impressive record of successfully building
commercial infrastructure and launching new medicines for
patients,” said Rachel Haurwitz, Ph.D., Caribou’s president and
chief executive officer. “We are delighted to welcome him to our
board of directors and look forward to benefitting from his
expertise as we continue to build our company and advance our
pipeline of chRDNA-edited allogeneic cell therapies for patients
with hematologic and solid tumors.”
“Caribou is making its mark as a leader in the allogeneic cell
therapy field, deploying its differentiated chRDNA technology to
create off-the-shelf cell therapies that may reach greater numbers
of patients globally than autologous cell therapies,” said Mr.
Johnson. “I look forward to working with the Caribou leadership
team and other board members as the company develops and advances
its pipeline.”
Mr. Johnson currently serves as chief commercial officer of
Global Blood Therapeutics where he leads the global commercial
functions that he built and which facilitated the launch of
Oxbryta® in 2019. Previously, Mr. Johnson spent 15 years at Gilead
Sciences, Inc., where he held roles of increasing responsibility in
the company’s commercial organization. He was instrumental in the
commercial launch of Gilead’s hepatitis C treatments Sovaldi®,
Harvoni®, Epclusa®, and Vosevi®, and its hepatitis B treatment
Vemlidy®. As vice president, sales and marketing, for Gilead’s
Antiviral Business Unit, he launched the HIV treatments Complera®
and Stribild®. Before Gilead, Mr. Johnson had an 11-year tenure at
Glaxo Smith Kline, where he held various positions in sales,
product marketing, business development, global commercial
strategy, and portfolio development. Mr. Johnson earned an M.B.A.
from the Kenan-Flagler Business School at the University of North
Carolina and a B.A. in business marketing from the University of
Puget Sound.
About Caribou’s Novel Next-Generation CRISPR
PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems are
capable of editing unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”)
that direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences,
Inc.Caribou Biosciences is a clinical-stage CRISPR
genome-editing biopharmaceutical company dedicated to developing
transformative therapies for patients with devastating diseases.
The company’s genome-editing platform, including its proprietary
Cas12a chRDNA technology, enables superior precision to develop
cell therapies that are specifically engineered for enhanced
persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T
and CAR-NK cell therapies for the treatment of patients with
hematologic malignancies and solid tumors.
Follow us @CaribouBio and visit www.cariboubio.com.
“Caribou Biosciences” and the Caribou logo are registered
trademarks of Caribou Biosciences, Inc.
Forward-Looking StatementsThis press release
contains forward-looking statements, within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, without limitation, statements
related to Caribou’s strategy, plans, and objectives, and
expectations regarding its clinical and preclinical development
programs, including its timing and expectations relating to the
release of clinical data from its ongoing ANTLER phase 1 clinical
trial for CB-010, the submission of IND applications for CB-011 and
CB-012, and target selection for CB-020. Management believes that
these forward-looking statements are reasonable as and when made.
However, such forward-looking statements are subject to risks and
uncertainties, and actual results may differ materially from any
future results expressed or implied by the forward-looking
statements. Risks and uncertainties include, without limitation,
risks inherent in development of cell therapy products;
uncertainties related to the initiation, cost, timing, progress,
and results of current and future research and development
programs, preclinical studies, and clinical trials; and the risk
that initial or interim clinical trial data will not ultimately be
predictive of the safety and efficacy of Caribou’s product
candidates or that clinical outcomes may differ as more data
becomes available; as well as other risk factors described from
time to time in Caribou’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year
ended December 31, 2021, and subsequent filings. In light of the
significant uncertainties in these forward-looking statements, you
should not rely upon forward-looking statements as predictions of
future events. Except as required by law, Caribou undertakes no
obligation to update publicly any forward-looking statements for
any reason.
Caribou Biosciences, Inc.
Contacts:Amy Figueroa, CFAInvestor Relations and
Corporate Communications afigueroa@cariboubio.com
Investors and Media:Elizabeth Wolffe, Ph.D.,
and Sylvia WheelerWheelhouse
LSAlwolffe@wheelhouselsa.comswheeler@wheelhouselsa.com
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024